This trial will test a new immunotherapy treatment for scleroderma, to see if it is safe and more effective than other treatments.
7 Primary · 6 Secondary · Reporting Duration: Disease response will be defined as subject improvement. This will be assessed for both skin and interstitial lung disease at 12 and 24 months post-HSCT.
Experimental Treatment
8 Total Participants · 1 Treatment Group
Primary Treatment: Total Body Irradiation · No Placebo Group · Phase 2
Age 8 - 60 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: